BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
54.09
-1.82 (-3.26%)
At close: Sep 12, 2025, 4:00 PM EDT
54.45
+0.36 (0.67%)
After-hours: Sep 12, 2025, 7:57 PM EDT
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $825.41M in the quarter ending June 30, 2025, with 15.92% growth. This brings the company's revenue in the last twelve months to $3.06B, up 18.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.06B
Revenue Growth
+18.36%
P/S Ratio
3.37
Revenue / Employee
$1,007,766
Employees
3,040
Market Cap
10.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BMRN News
- 4 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 5 days ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - PRNewsWire
- 7 days ago - BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - PRNewsWire
- 9 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 10 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 17 days ago - BioMarin to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 - Seeking Alpha